These natural compounds demonstrate considerable potential in modulating NF-κB signaling, thereby offering therapeutic benefits in attenuating inflammation-driven fibrotic progression in IPF. The gene discussed is NFKB1; the disease is idiopathic pulmonary fibrosis.